Display options
Cite
Frazier R, Mehta R, Cai X, et al. Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes. Kidney Int Rep. 2018;4(1):94-102doi: 10.1016/j.ekir.2018.09.006.
Frazier, R., Mehta, R., Cai, X., Lee, J., Napoli, S., Craven, T., Tuazon, J., Safdi, A., Scialla, J., Susztak, K., & Isakova, T. (2019). Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes. Kidney international reports, 4(1), 94-102. https://doi.org/10.1016/j.ekir.2018.09.006
Frazier, Rebecca, et al. "Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes." Kidney international reports vol. 4,1 (2019): 94-102. doi: https://doi.org/10.1016/j.ekir.2018.09.006
Frazier R, Mehta R, Cai X, Lee J, Napoli S, Craven T, Tuazon J, Safdi A, Scialla J, Susztak K, Isakova T. Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes. Kidney Int Rep. 2018 Sep 18;4(1):94-102. doi: 10.1016/j.ekir.2018.09.006. eCollection 2019 Jan. PMID: 30596172; PMCID: PMC6308372.
Copy Download .nbib Format: NLM
Share it on

Kidney Int Rep. 2018 Sep 18;4(1):94-102. doi: 10.1016/j.ekir.2018.09.006. eCollection 2019 Jan.

Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes.

Kidney international reports

Rebecca Frazier, Rupal Mehta, Xuan Cai, Jungwha Lee, Sara Napoli, Timothy Craven, Jennifer Tuazon, Adam Safdi, Julia Scialla, Katalin Susztak, Tamara Isakova

Affiliations

  1. Division of Nephrology and Hypertension, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  2. Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  3. Jesse Brown Veterans Administration Medical Center, Chicago, Illinois, USA.
  4. Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  5. Division of Nephrology, Department of Medicine, Duke University Medical Center, Duke University, Durham, North Carolina, USA.
  6. Division of Nephrology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

PMID: 30596172 PMCID: PMC6308372 DOI: 10.1016/j.ekir.2018.09.006

Abstract

INTRODUCTION: Abnormalities in lipid metabolism may contribute to the development and progression of chronic kidney disease (CKD) in patients with type 2 diabetes. Fenofibrate induces early and reversible reduction in estimated glomerular filtration rate (eGFR), but it may have protective effects on microvascular complications of diabetes. We hypothesized that randomization to fenofibrate versus placebo would be associated with beneficial long-term effects on kidney outcomes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial participants.

METHODS: We conducted a

RESULTS: We analyzed 2636 participants in the fenofibrate arm and 2632 in the placebo arm. During a median follow-up of 4 years, treatment with fenofibrate was associated with lower rate of eGFR decline (-0.28 ml/min per 1.73 m

CONCLUSION: Compared with placebo, randomization to fenofibrate was associated with lower rates of incident albuminuria and a slower eGFR decline, but no difference in incidence of CKD or kidney failure in ACCORD participants.

Keywords: albuminuria; chronic kidney disease; diabetic nephropathy; fenofibrate; kidney failure

References

  1. Nephron. 2002;92(3):536-41 - PubMed
  2. Am J Kidney Dis. 2004 Nov;44(5):917-20 - PubMed
  3. PLoS Med. 2005 Feb;2(2):e45 - PubMed
  4. Hypertension. 2005 Nov;46(5):1086-92 - PubMed
  5. Endocrinol Metab Clin North Am. 2006 Sep;35(3):491-510, vii-viii - PubMed
  6. Am J Cardiol. 2007 Jun 18;99(12A):21i-33i - PubMed
  7. J Pharmacol Exp Ther. 2008 Feb;324(2):658-63 - PubMed
  8. N Engl J Med. 2008 Jun 12;358(24):2545-59 - PubMed
  9. Curr Pharm Des. 2009;15(5):517-28 - PubMed
  10. Ann Intern Med. 2009 May 5;150(9):604-12 - PubMed
  11. N Engl J Med. 2010 Apr 29;362(17):1575-85 - PubMed
  12. N Engl J Med. 2010 Apr 29;362(17):1563-74 - PubMed
  13. Lancet. 2010 Aug 7;376(9739):419-30 - PubMed
  14. J Clin Invest. 2010 Oct;120(10):3443-54 - PubMed
  15. Diabetologia. 2011 Feb;54(2):280-90 - PubMed
  16. JAMA. 2011 Jun 22;305(24):2532-9 - PubMed
  17. Diabetes Care. 2012 May;35(5):1008-14 - PubMed
  18. Ann Intern Med. 2012 Apr 17;156(8):560-9 - PubMed
  19. J Am Heart Assoc. 2012 Feb;1(1):8-15 - PubMed
  20. J Am Soc Nephrol. 2013 Feb;24(2):302-8 - PubMed
  21. Am J Physiol Renal Physiol. 2014 Apr 15;306(8):F896-906 - PubMed
  22. N Engl J Med. 2014 Apr 17;370(16):1514-23 - PubMed
  23. Curr Diab Rep. 2015 Jul;15(7):40 - PubMed
  24. Diabetes Care. 2016 May;39(5):701-8 - PubMed
  25. N Engl J Med. 2016 Jul 28;375(4):323-34 - PubMed
  26. N Engl J Med. 2017 Aug 17;377(7):644-657 - PubMed
  27. N Engl J Med. 2017 Aug 31;377(9):839-848 - PubMed

Publication Types

Grant support